Gilead Just Dropped $5 Billion on a Munich Startup You've Never Heard Of

Behind that sits TUB-030, an earlier-stage ADC targeting the 5T4 protein across various solid tumors. Initial clinical data has been described as "promising," though details remain limited.

Neither of these will generate revenue anytime soon. But for Gilead, the real prize is what these programs represent: validation that the Tubulis platform works in humans, not just in petri dishes.

Why Gilead Is Going All-In on Cancer Missiles

Gilead built its empire on antiviral drugs. Its hepatitis C cures and HIV treatments generated enormous profits. But those franchises are maturing, and the company needs new growth engines.

Oncology has been the answer for years now. Gilead's existing ADC, Trodelvy (acquired through the $21 billion Immunomedics deal in 2020), brought in $1.4 billion in global sales last year. That's solid, but Trodelvy faces growing competition in a crowded field. Daiichi Sankyo's Enhertu has become a juggernaut, and dozens of other ADCs are in development across the industry.

The Tubulis acquisition is Gilead's bet that the next generation of ADC technology will matter more than the current one. RBC Capital Markets called it "a strategically sound bolt-on that addresses GILD's oncology pipeline growth needs while securing differentiated next-gen ADC platform capabilities."

And this is just one piece of a much bigger shopping spree. Gilead also dropped $7.8 billion on CAR T cell therapy developer Arcellx in February 2026 and $1.67 billion on Ouro Medicines. Three major acquisitions in three months. The company isn't dipping its toes into oncology anymore; it's cannonballing into the deep end.

From Spin-Out to $5 Billion in Six Years

Tubulis's origin story reads like a European biotech fairy tale. Co-founded by Dr. Dominik Schumacher and Dr. Jonas Helma-Smets around 2018, the company spun out of academic research at the Leibniz Research Institute for Molecular Pharmacology in Berlin and Ludwig Maximilian University in Munich.

The early days were humble: seed funding from angels and regional German investors, followed by a €10.7 million Series A led by BioMedPartners and High-Tech Gründerfonds. Then the momentum built fast. A $63 million Series B in 2022. A €128 million Series B2 in 2024. A massive $361 million Series C in 2025.

All told, Tubulis raised over $575 million in venture capital from a roster of top-tier biotech investors, including Venrock and EQT Life Sciences. Those investors are now getting a very handsome return on a company that never sold a single product.

The Bigger Picture: ADCs Are the New Arms Race

The ADC market has become one of the most competitive corners of oncology drug development. Multiple ADCs are already approved and transforming treatment across cancer types. But the field's dirty secret is that toxicity still limits how aggressively doctors can dose these drugs.

That's why "next-gen" platforms like Tubulis's are attracting so much attention. The companies that can solve the toxicity puzzle (through better linkers, site-specific conjugation, and engineered antibodies) will own the next decade of ADC development. It's not enough to have a guided missile anymore. You need one that doesn't blow up on the launchpad.

Gilead clearly decided it would rather buy that capability than build it from scratch. The two-year collaboration with Tubulis gave the company a front-row seat to evaluate the technology before writing a nine-figure check. And apparently, what Gilead saw convinced them to write a ten-figure one instead.

What Happens Next

Post-closing, Tubulis will operate as Gilead's ADC center of excellence in Munich. The deal is being financed by Gilead's existing cash reserves plus senior unsecured notes.

The big question is whether Tubulis's platform can deliver on its promise at scale. Lots of biotech platforms look great in early trials but stumble when they hit larger, more diverse patient populations. TUB-040's readouts over the next 12 to 18 months will be the first real stress test.

For now, Gilead is betting $5 billion that the future of cancer treatment isn't just about guided missiles. It's about guided missiles that don't hurt the people they're trying to save.

The Kidney Drug That Wasn't Supposed to Get Approved

Filspari just became the first FDA-approved treatment for FSGS, a rare kidney disease that's been without an approved therapy forever. The twist? The pivotal trial technically missed its main goal. How Travere pulled off the approval anyway is a story worth reading.